SCHEDULE: FMR LLC Discloses 6.3% Stake in Trevi Therapeutics

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 6.3% of Trevi Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson, through various subsidiaries and affiliates, collectively beneficially own 8,038,060.69 shares of Trevi Therapeutics Inc. common stock.
• This ownership stake represents 6.3% of the total outstanding common stock as of March 31, 2026.
• FMR LLC holds sole voting power for 8,025,496.00 shares and sole dispositive power for 8,038,060.69 shares.
• Abigail P. Johnson, who is the Director, Chairman, and CEO of FMR LLC, shares dispositive power over the 8,038,060.69 shares.
• The filing is an amendment to a previous Schedule 13G filing, indicating an update to ownership reporting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine ownership disclosure without specific performance or strategic information.

Positives

• FMR LLC and Abigail P. Johnson maintain a significant ownership stake, indicating confidence in Trevi Therapeutics.
• The reporting is conducted in accordance with SEC regulations, ensuring transparency for investors.

Negatives

• The filing does not provide specific details on the acquisition cost or strategy behind this ownership stake.
• No forward-looking statements or performance metrics are included in this ownership disclosure.

Risks

• The filing does not explicitly mention any risks associated with Trevi Therapeutics Inc. or the investment itself.
• Potential risks for FMR LLC and Abigail P. Johnson could include market volatility affecting the value of their investment in Trevi Therapeutics.

Future Outlook

This filing is a Schedule 13G amendment and does not contain forward-looking statements or specific guidance regarding Trevi Therapeutics Inc.'s future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant institutional ownership, as reported by FMR LLC, can often signal investor confidence and may influence market perception of Trevi Therapeutics within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially indicating stability or confidence in the company's prospects.
• Management of Trevi Therapeutics: The disclosure confirms a significant investor's ongoing interest.
• Potential Investors: The filing provides transparency on a major shareholder's stake.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to report any changes in beneficial ownership as required by SEC regulations.

Key Dates

Keywords

Trevi Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, SEC Filing, Beneficial Ownership, Common Stock, Investment, Securities, Ownership Stake